Pulmonary Fibrosis refers to the development of excessive scar tissue within the lung, particularly within the interstitial and alveolar structures, causing the normally delicate gas-exchange architecture to become thickened, distorted and less compliant. Fibrosis is not a single disease but a pathological process that occurs in numerous conditions. Scar formation can follow autoimmune inflammation, occupational or environmental exposure, certain medications, radiation, infections or other injuries, while in some cases no definite cause is identified.
When the cause remains unknown in an appropriate clinical setting, a specific form called idiopathic pulmonary fibrosis may be diagnosed. The essential physiological consequences are reduced lung compliance, impaired diffusion of oxygen across the alveolar-capillary interface and increased work of breathing. Patients often develop progressive exertional breathlessness and a persistent dry cough. As fibrosis advances, oxygenation can deteriorate, exercise capacity falls and respiratory failure may develop. The term "fibrosis" describes structural scarring rather than simply any inflammation of the lungs, and distinguishing active inflammation from established irreversible scar is important because treatment responsiveness varies according to the underlying disease and stage.
The causes of Pulmonary Fibrosis are numerous and include connective-tissue diseases, inhalational exposures, occupational dusts, certain drugs and therapeutic radiation. Autoimmune diseases can generate chronic immune-mediated injury to the alveolar epithelium and other lung structures, eventually leading to fibrosis. Exposure to asbestos, silica, certain metals, agricultural materials and other inhaled particles can produce occupational interstitial lung disorders. Some medications have recognised pulmonary toxicity, and radiation can cause an inflammatory phase followed by fibrotic change in exposed tissue.
Previous severe infection or acute lung injury can occasionally leave residual fibrosis. Idiopathic pulmonary fibrosis is characterised by a specific clinical, radiological and pathological pattern in the absence of an identified cause rather than simply meaning "fibrosis of unknown severity". Genetic predisposition can influence susceptibility in some families, and age-related epithelial repair abnormalities are important in several fibrotic diseases. Identifying the cause is critical because removing an exposure, treating an autoimmune disease or stopping a causative medicine can alter the disease trajectory, whereas established scar tissue may not reverse even after the initiating factor has been eliminated.
Fibrotic lung injury involves complex interactions among alveolar epithelial cells, immune cells, fibroblasts and extracellular-matrix proteins. Repeated or persistent epithelial injury can trigger signalling pathways that activate fibroblasts and myofibroblasts. These cells produce excessive collagen and other matrix components, causing thickening and distortion of the interstitium. Normal tissue architecture becomes progressively replaced by scar, and neighbouring alveoli can collapse or become structurally distorted. In certain fibrotic patterns, microscopic cystic spaces called honeycombing develop as terminally damaged lung units become remodelled.
Fibrosis reduces lung compliance, meaning greater pressure is required to produce a given change in lung volume. The work of breathing consequently increases. Thickening of the alveolar-capillary interface impairs diffusion, particularly during exercise when pulmonary capillary transit time is shortened. Pulmonary vascular remodelling can develop as functional capillary beds are lost or compressed, contributing to pulmonary hypertension. These mechanisms explain why pulmonary fibrosis can cause profound exertional limitation even when resting measurements remain comparatively preserved early in the disease.
Evaluation commonly includes high-resolution computed tomography, pulmonary function testing, exposure history, autoimmune assessment and, when necessary, multidisciplinary review. Computed tomography can reveal characteristic patterns such as reticulation, architectural distortion, traction bronchiectasis and honeycombing, although the exact combination and distribution determine the likely diagnosis. Spirometry often demonstrates a restrictive pattern, with reduced forced vital capacity, while diffusing capacity may be disproportionately impaired. Exercise testing can reveal oxygen desaturation and reduced functional capacity that are not apparent at rest.
Blood tests can identify autoimmune markers or other clues but are not sufficient by themselves to establish a specific fibrotic diagnosis. In selected cases, bronchoscopy, bronchoalveolar lavage or lung biopsy may be considered, although tissue sampling is not necessary when imaging and clinical information provide a sufficiently characteristic diagnosis and biopsy risk would outweigh benefit. Multidisciplinary interpretation is particularly valuable because several interstitial diseases have overlapping imaging and pathological features.
Treatment depends strongly on the cause and fibrotic pattern. Avoidance of ongoing occupational or environmental exposure is essential when an inhalational trigger has been identified. Autoimmune-associated fibrosis may require immunomodulatory treatment directed at the underlying inflammatory disease, while established fibrotic progression may require antifibrotic medicines in appropriate conditions.
Antifibrotic therapies act on biological pathways involved in fibrogenesis and can slow decline in lung function in selected progressive fibrotic disorders, but they do not generally remove established scar tissue or restore normal lung architecture. Supportive management includes pulmonary rehabilitation, exercise within individual limits, oxygen therapy for appropriate hypoxaemia and treatment of associated conditions. Vaccination and infection prevention are particularly important because respiratory infections can cause substantial deterioration. Smoking cessation is relevant even when smoking is not the primary cause. Medication selection requires attention to adverse effects, liver function, drug interactions and the exact diagnostic category, because therapies effective for one fibrotic disease may be ineffective or harmful in another.
Pulmonary Fibrosis can progress gradually or accelerate through acute deteriorations. Acute exacerbations of some fibrotic disorders involve sudden worsening of breathlessness and new widespread lung abnormalities, often with severe hypoxaemia. Respiratory infections, pulmonary embolism, heart failure and other complications can mimic or precipitate deterioration and therefore require careful assessment. Pulmonary hypertension can substantially worsen exercise capacity and prognosis by increasing right-heart workload and reducing pulmonary vascular reserve.
Gastro-oesophageal reflux, sleep-disordered breathing, osteoporosis, anxiety, depression and nutritional problems may coexist and influence overall health. Advanced disease can lead to chronic respiratory failure and increasing oxygen requirements. Lung transplantation is an important option for selected people with advanced progressive fibrotic disease who meet appropriate criteria, although eligibility depends on age, comorbidity, functional status and other factors. Palliative care can be integrated alongside disease-directed therapy to address breathlessness, cough, functional decline and future care planning.
The history of pulmonary fibrosis reflects changing concepts in lung pathology. Earlier classifications often grouped many distinct disorders under broad descriptions of diffuse interstitial disease, whereas modern high-resolution imaging, immunology, genetics and multidisciplinary diagnosis have produced more precise categories. The distinction between inflammation and fibrosis is particularly important because inflammatory lung injury can sometimes improve substantially with treatment, while established fibrosis is comparatively resistant to reversal.
However, inflammation and fibrosis are not completely separate processes; immune signalling, epithelial injury and fibroblast activation can interact continuously. The term should therefore not be used as though every instance represents the same biological mechanism. Idiopathic pulmonary fibrosis is one specific progressive fibrotic lung disease and should not be used as a synonym for Pulmonary Fibrosis in general. This distinction is essential for interpreting research, prognosis and treatment because different causes and patterns have markedly different natural histories and therapeutic options.
A major misconception is that Pulmonary Fibrosis means the lungs are simply "scarred from an old infection" and therefore cannot change further. Some fibrotic disorders are indeed residual consequences of previous injury, but others are active progressive diseases in which fibrotic remodelling continues over time. Another misconception is that every person with fibrosis experiences the same prognosis. Disease behaviour varies according to cause, radiological pattern, extent, rate of progression, comorbidities and treatment response.
Pulmonary Fibrosis also differs from emphysema in its basic mechanics: fibrosis generally produces stiff, low-volume lungs and impaired diffusion, whereas emphysema produces loss of elastic recoil, hyperinflation and increased lung compliance. These processes can coexist, creating complex physiology. The condition is therefore best understood as a family of structural fibrotic processes rather than one uniform illness, with accurate classification providing the foundation for meaningful prognosis, treatment and monitoring.
